Paradigm Biopharmaceuticals receives written feedback from FDA relating to IND submission Pentosan polysulfate sodium (PPS) is currently being evaluated by Paradigm for potential registration for the treatment of osteoarthritis and other inflammatory diseases in the US and other major global markets. The FDA response requires further clarification on one remaining question. Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received written feedback from the US Food and Drug Administration (FDA) on July 30, 2021 regarding Paradigm’s Investigational New Drug (IND) application submitted on March 26, 2021. The company previously reported it had received written feedback from the US FDA, requesting answers to six questions relating to Paradigm’s IND submission.